An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's D...

Autores
Bordet, Sofía; Grasso, Lina; Udovin, Lucas; Chevalier, Guenson; Otero-Losada, Matilde; Capani, Francisco; Pérez-Lloret, Santiago
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Bordet, Sofía. Universidad Abierta Interamericana; Argentina
Fil: Bordet, Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Bordet, Sofía. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; Argentina
Fil: Grasso, Lina. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; Argentina
Fil: Udovin, Lucas. Universidad Abierta Interamericana; Argentina
Fil: Udovin, Lucas. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Chevalier, Guenson. Universidad Abierta Interamericana; Argentina
Fil: Chevalier, Guenson. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Otero-Losada, Matilde. Universidad Abierta Interamericana; Argentina
Fil: Otero-Losada, Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Capani, Francisco. Universidad Abierta Interamericana; Argentina
Fil: Capani, Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Capani, Francisco. Universidad Aut onoma de Chile; Chile
Fil: Pérez-Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; Argentina
Fil: Pérez-Lloret, Santiago. Universidad de Buenos Aires; Argentina
Background: The cerebral Renin-Angiotensin System might have a role in anxiety and depression development. Objective: We explored the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) on anxiety and depression in Parkinson’s Disease (PD). Methods: Four hundred and twenty-three newly diagnosed drug-naïve PD patients were evaluated using the State–Trait Anxiety Inventory (STAI) and Geriatric Depression Scale (GDS-15) tests and were monitored at baseline and for up to 3 years. Results: Twelve patients were treated with ARBs and 42 with ACE-Is. ARB-treated patients had lower anxiety STAI scores than those on ACE-Is or drug-free at baseline (17.2 1.3 vs. 21.3 1.3, or 23.8 0.5, respectively, P = 0.021) and during the follow-up (P < 0.01). Depression scores were unaffected by any of the drugs throughout the study. Conclusion: This small sample of ARB-treated PD patients displayed lower levels of anxiety. Randomized clinical trials are warranted.
Fuente
Movement Disorders Clinical Practice. 12(5), 2025.
Materia
ENFERMEDAD DE PARKINSON
DEPRESION
ANSIEDAD
ANGIOTENSINA II
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/20021
Acceder
id RIUCA_beaebd6495f852493bc87dfbe34cb933
oai_identifier_str oai:ucacris:123456789/20021
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's DiseaseBordet, SofíaGrasso, LinaUdovin, LucasChevalier, GuensonOtero-Losada, MatildeCapani, FranciscoPérez-Lloret, SantiagoENFERMEDAD DE PARKINSONDEPRESIONANSIEDADANGIOTENSINA IIFil: Bordet, Sofía. Universidad Abierta Interamericana; ArgentinaFil: Bordet, Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Bordet, Sofía. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; ArgentinaFil: Grasso, Lina. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; ArgentinaFil: Udovin, Lucas. Universidad Abierta Interamericana; ArgentinaFil: Udovin, Lucas. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Chevalier, Guenson. Universidad Abierta Interamericana; ArgentinaFil: Chevalier, Guenson. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Otero-Losada, Matilde. Universidad Abierta Interamericana; ArgentinaFil: Otero-Losada, Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Capani, Francisco. Universidad Abierta Interamericana; ArgentinaFil: Capani, Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Capani, Francisco. Universidad Aut onoma de Chile; ChileFil: Pérez-Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; ArgentinaFil: Pérez-Lloret, Santiago. Universidad de Buenos Aires; ArgentinaBackground: The cerebral Renin-Angiotensin System might have a role in anxiety and depression development. Objective: We explored the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) on anxiety and depression in Parkinson’s Disease (PD). Methods: Four hundred and twenty-three newly diagnosed drug-naïve PD patients were evaluated using the State–Trait Anxiety Inventory (STAI) and Geriatric Depression Scale (GDS-15) tests and were monitored at baseline and for up to 3 years. Results: Twelve patients were treated with ARBs and 42 with ACE-Is. ARB-treated patients had lower anxiety STAI scores than those on ACE-Is or drug-free at baseline (17.2 1.3 vs. 21.3 1.3, or 23.8 0.5, respectively, P = 0.021) and during the follow-up (P < 0.01). Depression scores were unaffected by any of the drugs throughout the study. Conclusion: This small sample of ARB-treated PD patients displayed lower levels of anxiety. Randomized clinical trials are warranted.International Parkinson and Movement Disorder Society2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/2002110.1002/mdc3.14326Movement Disorders Clinical Practice. 12(5), 2025.reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-11-13T10:18:51Zoai:ucacris:123456789/20021instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-11-13 10:18:52.181Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
spellingShingle An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
Bordet, Sofía
ENFERMEDAD DE PARKINSON
DEPRESION
ANSIEDAD
ANGIOTENSINA II
title_short An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_full An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_fullStr An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_full_unstemmed An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_sort An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
dc.creator.none.fl_str_mv Bordet, Sofía
Grasso, Lina
Udovin, Lucas
Chevalier, Guenson
Otero-Losada, Matilde
Capani, Francisco
Pérez-Lloret, Santiago
author Bordet, Sofía
author_facet Bordet, Sofía
Grasso, Lina
Udovin, Lucas
Chevalier, Guenson
Otero-Losada, Matilde
Capani, Francisco
Pérez-Lloret, Santiago
author_role author
author2 Grasso, Lina
Udovin, Lucas
Chevalier, Guenson
Otero-Losada, Matilde
Capani, Francisco
Pérez-Lloret, Santiago
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv ENFERMEDAD DE PARKINSON
DEPRESION
ANSIEDAD
ANGIOTENSINA II
topic ENFERMEDAD DE PARKINSON
DEPRESION
ANSIEDAD
ANGIOTENSINA II
dc.description.none.fl_txt_mv Fil: Bordet, Sofía. Universidad Abierta Interamericana; Argentina
Fil: Bordet, Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Bordet, Sofía. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; Argentina
Fil: Grasso, Lina. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; Argentina
Fil: Udovin, Lucas. Universidad Abierta Interamericana; Argentina
Fil: Udovin, Lucas. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Chevalier, Guenson. Universidad Abierta Interamericana; Argentina
Fil: Chevalier, Guenson. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Otero-Losada, Matilde. Universidad Abierta Interamericana; Argentina
Fil: Otero-Losada, Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Capani, Francisco. Universidad Abierta Interamericana; Argentina
Fil: Capani, Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Capani, Francisco. Universidad Aut onoma de Chile; Chile
Fil: Pérez-Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Psicología y Psicopedagogía; Argentina
Fil: Pérez-Lloret, Santiago. Universidad de Buenos Aires; Argentina
Background: The cerebral Renin-Angiotensin System might have a role in anxiety and depression development. Objective: We explored the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) on anxiety and depression in Parkinson’s Disease (PD). Methods: Four hundred and twenty-three newly diagnosed drug-naïve PD patients were evaluated using the State–Trait Anxiety Inventory (STAI) and Geriatric Depression Scale (GDS-15) tests and were monitored at baseline and for up to 3 years. Results: Twelve patients were treated with ARBs and 42 with ACE-Is. ARB-treated patients had lower anxiety STAI scores than those on ACE-Is or drug-free at baseline (17.2 1.3 vs. 21.3 1.3, or 23.8 0.5, respectively, P = 0.021) and during the follow-up (P < 0.01). Depression scores were unaffected by any of the drugs throughout the study. Conclusion: This small sample of ARB-treated PD patients displayed lower levels of anxiety. Randomized clinical trials are warranted.
description Fil: Bordet, Sofía. Universidad Abierta Interamericana; Argentina
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/20021
10.1002/mdc3.14326
url https://repositorio.uca.edu.ar/handle/123456789/20021
identifier_str_mv 10.1002/mdc3.14326
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv International Parkinson and Movement Disorder Society
publisher.none.fl_str_mv International Parkinson and Movement Disorder Society
dc.source.none.fl_str_mv Movement Disorders Clinical Practice. 12(5), 2025.
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1848683875461496832
score 13.25334

Publicaciones similares